KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
The treatment of multiple myeloma has advanced considerably in recent years with Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remaining key cornerstones of treatment…
MARKET OUTLOOK Dyslipidemia is an important modifiable risk factor for CV disease and is primarily managed with statin therapy. Based on the positive CVOT data for certain nonstatin therapies,…
MARKET OUTLOOK Rheumatoid arthritis (RA) patients refractory to one or more TNF-α inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol-Myers Squibb’s Orencia, Roche’…
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy despite the availability of several treatment options. Resistance to therapy is the primary treatment challenge associated…
Obesity is arguably the most pressing public health issue in the United States. The prevalence of obesity is extremely high, and its chronic progression is associated with type 2 diabetes and…
DRG epidemiologists estimate that 40% of epilepsy patients experience generalized-onset seizures (GOS). The most commonly prescribed early-line treatments for GOS are older antiepileptic drugs (…
DRG epidemiologists estimate that 60% of epilepsy patients experience partial-onset seizures (POS), which aretypically the gateway indication for new antiepileptic drugs (AEDs). The most frequently…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
A comprehensive, quantitative understanding of patient progression through all stages of disease management and treatment is critical in both assessing a market opportunity within a therapeutic…
The multiple myeloma therapy market has witnessed considerable advances in recent years. Effective therapies such as Thalomid, Revlimid, Velcade, Pomalyst, and Kyprolis have transformed the…
DRG Epidemiology's coverage of neuroendocrine tumor comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Gastroesophageal reflux disease (GERD) is arguably the most common chronic gastrointestinal disorder, characterized by symptoms of heartburn and regurgitation. The primary objectives of GERD…
DRG Epidemiology’s coverage of Tay-Sachs disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
DRG Epidemiology’s coverage of Krabbe disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…